At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 46 enrolled
Drug / intervention
ZH9PA and ZH9 +2 morebiological
Likely dose
ZH9PA and ZH9 150mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Randomised, Double-blind, Placebo-controlled, Parallel Group Dose Escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of a Potential Oral Enteric Fever Vaccine (ZH9 + ZH9PA) in Healthy Participants
In Brief
A Phase 1 clinical trial evaluating ZH9PA and ZH9, Placebo, and 1 other intervention for Enteric Fever. Completed, enrolled 46 participants across 1 site.
Detailed Summary
A Phase 1, randomised, double-blind, placebo-controlled, parallel group study in 45 healthy participants aged 18 to 45 years inclusive.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEnteric Fever
CountriesUnited Kingdom
CollaboratorsSimbec Research
Timeline
Phase 1CompletedFinished
2020202120222023202420252026
Enrollment StartDec 2019
First PostedApr 2020
Primary CompletionSep 2020
Study CompletionFeb 2021
TodayJul 2026
First PostedApr 16, 2020
Enrollment StartDec 16, 2019
Primary CompletionSep 28, 2020
Study CompletionFeb 15, 2021
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 6.2 years ago
Interventions
ZH9PA and ZH9biological
150mL vaccine for oral administration
Placebobiological
150mL vaccine for oral administration
ZH9PAbiological
150mL vaccine for oral administration